GIHSN Data Sharing Agreement
2024-2025

The Global Influenza Hospital Surveillance Network (GIHSN) is a platform that collects standardized data from hospitalized patients with severe acute respiratory illnesses[1] across countries, including low-, middle-, and high-income countries from both hemispheres. The GIHSN has evolved over the last 12 years to focus on linking epidemiologic and clinical data with Whole Genome Sequencing information to facilitate exploring viral phenotypes as they relate to severity or vaccine breakthrough cases.

The GIHSN is supported by a dedicated fund, the *Foundation for Influenza Epidemiology*, which is hosted by Fondation de France, a leading philanthropy organisation in France. Coordination of the GIHSN, supervision of implementation and data management/data hosting are supported by Impact Healthcare, an independent organization based in Paris, France, specializing in the strategic and operational management of large innovative projects in Digital Health and the use of Health data, both in France and internationally.

To comply with regulations on data access and privacy, the Foundation for Influenza Epidemiology set up a data access framework for the GIHSN. Impact Healthcare is the Data Controller, jointly with Fondation de France. Impact Healthcare is proposing an online data collection tool to ensure timely data sharing on the GIHSN platform.

The GIHSN database is hosted in a secured environment (certified secured hosting for health personal data). Data is processed in full accordance with the European General Data Protection Regulation (GDPR) and French data protection regulations.

Sites implementing the GIHSN protocol should be compliant with their ethical and national regulations for conducting the surveillance. Any obligation related to data protection and data transfer to Impact Healthcare platform should be anticipated.

Data collected by sites receiving funding remains the proprietary of the site. There is no commercial use of the data. Donors of the Foundation for Influenza Epidemiology, who include, as of November 2024, Sanofi, Seqirus, Abbott Diagnostics, Pfizer do not have access to the data. The data is transferred through a secured channel and the site has full access to the data that was shared, through a secured platform managed by Impact Healthcare.

Influenza strain genetic sequencing data will be shared via GISAID.

Impact Healthcare is given access to the GIHSN database for epidemiologic research fulfilling the three following conditions:

---

[1] See GIHSN core protocol [link] and questionnaire [link]

- Analyses can only be performed for research purposes in line with the mandate of the Foundation (i.e. surveillance and monitoring of influenza and other respiratory viruses).

- Analyses are exclusively performed with **anonymised data**.

- Any analyses plan will need to be approved **beforehand** by the Independent Scientific Committee of the Foundation.

Aggregated surveillance data by site is reported on a yearly basis in the GIHSN Annual Report. It is also displayed in the form of aggregated indicators and graphs accessible via the GIHSN website.

Some surveillance data collected through the GIHSN may be shared with WHO. Sites will be informed.

Analysis results are submitted for publication. Scientific publications and communications will mention contributing sites, with investigators names in the authorship, in line with the ICMJE rules.

Sites will be informed upfront for any planned data analysis beyond the routine annual pooled analysis, and **they have the possibility to opt-out.** Any research project leveraging on the GIHSN data must be approved beforehand by the Scientific Committee of the GIHSN and the Foundation for Influenza Epidemiology. Only anonymised data is shared.

Considering these rules, and to allow for continued analysis of both historical and current seasonal data, I hereby agree to share with Impact Healthcare the data collected at site level, according to the GIHSN protocol and questionnaire.

First and Last Name	
Name and address of institution	
Country/region	

Date

_____

Signature

_____